Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880602 | 0.81 | OPRM1 (0.75) | OPRM1OPRK1OPRL1MPOKCNH2 | |
| SCHEMBL4873298 | 0.76 | OPRM1 (0.49) | OPRM1OPRK1OPRL1MPOSOS1 | |
| SCHEMBL4873314 | 0.69 | OPRM1 (0.45) | OPRM1OPRK1OPRL1KCNH2SLC6A4 | |
| SCHEMBL14280672 | 0.68 | OPRM1 (1.00) | OPRM1OPRK1OPRL1KCNH2SLC6A4 | |
| SCHEMBL13375737 | 0.65 | MPO (0.69) | OPRM1OPRK1OPRL1MPOSOS1 | |
| SCHEMBL14280689 | 0.65 | OPRM1 (0.64) | OPRM1OPRK1OPRL1SLC6A4DRD2 | |
| SCHEMBL14375346 | 0.65 | MPO (0.72) | OPRM1OPRK1OPRL1MPOSOS1 | |
| SCHEMBL14280681 | 0.63 | OPRM1 (0.79) | OPRM1OPRK1OPRL1CHRM1 | |
| SCHEMBL14280683 | 0.63 | OPRM1 (0.57) | OPRM1OPRK1OPRL1SLC6A4 | |
| SCHEMBL13374358 | 0.62 | MPO (0.67) | OPRM1OPRK1OPRL1MPOSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | OPRM1 11/4885OPRK1 5/4885OPRL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.